Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/119745
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHall, R.en
dc.contributor.authorAspinall, J.en
dc.contributor.authorHorsfall, D.en
dc.contributor.authorBirrell, S.en
dc.contributor.authorBentel, J.en
dc.contributor.authorSutherland, R.en
dc.contributor.authorTilley, W.en
dc.date.issued1996en
dc.identifier.citationBritish Journal of Cancer, 1996; 74(8):1175-1180en
dc.identifier.issn0007-0920en
dc.identifier.issn1532-1827en
dc.identifier.urihttp://hdl.handle.net/2440/119745-
dc.description.abstractLittle is known regarding the activity and function of the androgen receptor (AR) in human breast cancer. In the present study AR was evaluated in untreated primary breast cancers using antisera to the amino- and carboxy-termini of the receptor and quantitated using colour video image analysis. A strong correlation between tissue concentration and percentage AR-positive cells was observed for each antiserum. However, comparison of percentage positive cells using the amino- and carboxy-terminal AR antisera in individual breast cancer specimens revealed a subset of tumours with discordantly increased staining for the carboxy terminus. These findings suggest the presence of amino-terminal-truncated AR in a proportion of breast cancer cells or presence of AR mutations or associated protein alterations that affect binding of the amino-terminal AR antiserum. Immunohistochemical expression of the androgen-regulated glycoprotein, apolipoprotein D (apo-D), was also evaluated in the breast cancer specimens. Focal positivity of apo-D staining, which did not always co-localise with AR-positive cells, was observed within breast tumours. Furthermore, no correlation was evident between percentage positive cells stained for AR and apo-D in breast cancer specimens. These findings indicate that, although apo-D expression is androgen regulated in human breast cancer cell lines in vitro, its expression in primary breast cancers may be regulated by other factors. The expression of AR in primary breast cancers also suggests that the receptor may be involved in tumour responsiveness or in abnormal responses to endocrine therapies.en
dc.description.statementofresponsibilityR.E. Hall, J.O. Aspinall, D.J. Horsfall, S.N. Birrell, J.M. Bentel, R.L. Sutherland and W.D. Tilleyen
dc.language.isoenen
dc.publisherStockton Pressen
dc.rights© 1996 Stockton Press. All rights reserved.en
dc.subjectAndrogen receptor; breast cancer; immunohistochemistry; apolipoprotein Den
dc.titleExpression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast canceren
dc.typeJournal articleen
dc.identifier.rmid0030072820en
dc.identifier.doi10.1038/bjc.1996.513en
dc.identifier.pubid362074-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS10en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidTilley, W. [0000-0003-1893-2626]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.